Notice of Proposed Sale · 144/A
Amgen Inc.
AMGNNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144/A
primary_doc.xml
Amendment · This filing reports the amendment as submitted.
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- AMGEN INC
- Issuer CIK
- 0000318154
- SEC file number
- 001-37702
- Phone
- (805)447-1000
- Person for whose account securities are to be sold
- Grygiel Nancy A.
- Relationships to issuer
- Officer
- Street
- ONE AMGEN CENTER DRIVE
- City
- THOUSAND OAKS
- State / country code
- CA
- Postal code
- 91320
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 2,970 | 1,193,940.00 | 539,000,000 | 08/06/2026 | NASDAQ | Raymond James & Associates |
Broker / market maker — proposed row 1, entry 1
- Name
- Raymond James & Associates
- Street
- 880 Carillon Parkway
- City
- St. Petersburg
- State / country code
- FL
- Postal code
- 33716
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 04/27/2018 | Cashless Stock Option Exercise | Amgen Inc | 1,970 | N | 08/06/2026 | Cash |
| Common | 05/03/2019 | Cashless Stock Option Exercise | Amgen Inc | 1,000 | N | 08/06/2026 | Cash |
Prior-sale reporting
- Nothing to report for the preceding three months
- Y
Notice signature
- Notice date
- 08/06/2026
- Signed
- Rashida Mitchell, as duly authorized representative of Raymond James & Associates, Inc., as attorney-in-fact for Nancy A Grygiel
Company context
Amgen discovers, develops, manufactures and delivers innovative medicines to fight some of the world’s toughest diseases. Harnessing the best of biology and technology, Amgen reaches millions of patients with its medicines. More than 45 years ago, Amgen helped establish the biotechnology industry at its U.S. headquarters in Thousand Oaks, California, and it remains at the cutting edge of innovation, using technology and human genetic data to push beyond what is known today. Amgen is advancing a broad and deep pipeline and portfolio of medicines to treat cancer, inflammatory conditions, rare diseases, heart disease and obesity and obesity-related conditions.